Invivyd, Inc.
IVVD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IVVD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IVVD
Invivyd, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies for the prevention and treatment of viral infectious diseases, with its first authorized product PEMGARDA and a pipeline including VYD2311, VBY329, and VMS063.
Key risk: Uncertain revenue and cash flow
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Invivyd, Inc..
Invivyd, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies for the prevention and treatment of viral infectious diseases, with its first authorized product PEMGARDA and a pipeline including VYD2311, VBY329, and VMS063.
- Invivyd’s first product, PEMGARDA, is authorized for use and generates revenue, though the company remains dependent on continued authorization and commercial success [sec_mda · as of 2026-08-13].
- As of June 30, 2026, Invivyd reported cash and equivalents of $160.1M, total revenue of $14.3M, and a net loss of -$44.4M [latest reported financials].
- The company is advancing a pipeline including VYD2311, VBY329, and VMS063, and is conducting the REVOLUTION clinical program [sec_mda · as of 2026-08-13].
- Invivyd has historically financed operations through equity offerings, including $464.7M from preferred stock, $327.5M from its IPO, and $92.1M from common stock sales [sec_mda · as of 2026-08-13].
- The company relies on third parties for clinical trials, manufacturing, and research, including a partnership with Adimab for antibody discovery [sec_mda · as of 2026-08-13].
What works
- Invivyd has an authorized product (PEMGARDA) generating revenue, providing a commercial foothold and potential cash flow [sec_mda · as of 2026-08-13].
- The company has raised substantial capital through equity offerings, with $160.1M in cash as of June 30, 2026, to fund operations and pipeline development [latest reported financials].
- Invivyd is advancing a diversified pipeline of monoclonal antibody candidates (VYD2311, VBY329, VMS063) targeting viral infectious diseases, with the REVOLUTION clinical program underway [sec_mda · as of 2026-08-13].
What to weigh
- Invivyd has a history of net losses, reporting a net loss of -$44.4M for the six months ended June 30, 2026, and expects expenses to increase as development and commercialization activities expand [latest reported financials] [sec_mda · as of 2026-08-13].
- The company is uncertain when, if ever, material net cash inflows from product sales will commence beyond PEMGARDA, and will require additional funding through equity, debt, or partnerships [sec_mda · as of 2026-08-13].
- Invivyd depends on third parties for clinical trials, manufacturing, and key technology (Adimab platform), creating operational and supply-chain risks [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Invivyd is uncertain about the timing of material net cash inflows from product sales.
“We are also unable to predict when, if ever, material 30 net cash inflows will commence from sales or licensing of our product candidates.”
SEC MD&A · August 13, 2026
The company relies on third parties for key activities.
“In addition, we expect to continue to rely on third parties for clinical trials and the manufacture and testing of our product candidates, as well as to perform ongoing research and development and other services on our behalf.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Uncertain revenue and cash flow — Invivyd cannot predict when material net cash inflows from product sales will commence beyond PEMGARDA [sec_mda · as of 2026-08-13].
- Need for additional funding — The company will require additional funding through equity, debt, or partnerships, which may not be available on favorable terms [sec_mda · as of 2026-08-13].
- Dependence on third parties — Invivyd relies on third parties for clinical trials, manufacturing, and key technology (Adimab), creating operational risks [sec_mda · as of 2026-08-13].
- History of net losses — Invivyd reported a net loss of -$44.4M for the six months ended June 30, 2026, and expects expenses to increase [latest reported financials] [sec_mda · as of 2026-08-13].
What to watch
- Progress of the REVOLUTION clinical program and pipeline candidates VYD2311, VBY329, and VMS063 [sec_mda · as of 2026-08-13].
- Revenue trends from PEMGARDA and its continued regulatory authorization [sec_mda · as of 2026-08-13].
- Cash runway and any future equity or debt financing activities [latest reported financials] [sec_mda · as of 2026-08-13].
- Updates on third-party manufacturing and clinical trial execution [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Invivyd, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Invivyd, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
11.6 months
D/E 0.21 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
137
Total value held
$342.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 66,188,660 | $85.7M |
| perceptive advisors llc | 41,718,606 | $54.2M |
| vanguard capital management llc | 20,148,652 | $26.2M |
| bvf inc/il | 19,525,000 | $25.4M |
| maverick capital ltd | 18,970,913 | $24.7M |
| eventide asset management, llc | 9,071,995 | $11.8M |
| driehaus capital management llc | 8,436,894 | $11.0M |
| state street corp | 6,935,648 | $9.0M |
| blackrock, inc. | 4,281,790 | $5.6M |
| siren, l.l.c. | 4,000,000 | $5.2M |
Showing top 10 of 137 institutional holders of Invivyd, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 11.5%
- Days to cover
- 8.7
- Shares short
- 29,263,723
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IVVD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Invivyd, Inc.?
Invivyd, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies for the prevention and treatment of viral infectious diseases, with its first authorized product PEMGARDA and a pipeline including VYD2311, VBY329, and VMS063.
What is Invivyd, Inc.'s lead drug candidate?
Invivyd, Inc.'s most advanced tracked candidate is adintrevimab (Phase 2/Phase 3) for Prevention and treatment of COVID-19.
Who is the CEO of Invivyd, Inc.?
Pharmaceuticals Incorporated is the chief executive officer of Invivyd, Inc. (IVVD).
Where is Invivyd, Inc. headquartered?
Invivyd, Inc. (IVVD) is headquartered in New Haven, CT, United States.
What therapeutic areas does Invivyd, Inc. focus on?
Invivyd, Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.